Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.62 |
| ▸ | HTR2C | P28335 | 9/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573411 | 0.91 | HTR2A (0.75) | HTR2AHTR2C | |
| SCHEMBL5057269 | 0.91 | HTR2A (0.75) | HTR2AHTR2C | |
| SCHEMBL5057323 | 0.87 | HTR2A (0.61) | HTR2AHTR2CKDRMAPTMEN1 | |
| SCHEMBL29573160 | 0.87 | HTR2A (0.61) | HTR2AHTR2CKDRMAPTMEN1 | |
| SCHEMBL29573185 | 0.86 | HTR2A (0.60) | HTR2AHTR2CKDRMAPTPDGFRA | |
| SCHEMBL5063292 | 0.86 | HTR2A (0.60) | HTR2AHTR2CKDRMAPTPDGFRA | |
| SCHEMBL5057440 | 0.85 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL29573188 | 0.85 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL20266852 | 0.83 | HTR2A (0.68) | HTR2AHTR2CMAPTMEN1KMT2A | |
| SCHEMBL5652059 | 0.82 | HTR2A (0.84) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273035-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | claimed |
| US-20150073141-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-03-12 | — | — | US | claimed |
| US-8871797-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | claimed |
| US-8754238-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-20130237541-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20080200530-A1 | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| EP-1843762-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS OR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | Arena Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070078134-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| US-20070072857-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | claimed |
| EP-1695966-A1 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2006-08-30 | — | — | EP | claimed |
| WO-2006078610-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS OR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| EP-1558582-B1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-12-21 | — | — | EP | claimed |
| EP-1558582-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTIALS, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005012254-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885KDR 1251/4885 |
| US-20080200530-A1 | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885KDR 425/4885 |
| US-20070078134-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885KDR 1251/4885 |
| US-20070072857-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885KDR 1251/4885 |
| US-20130237541-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885KDR 2681/4885 |
| US-20150073141-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885KDR 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.